EPGN: A NAD+-Dependent Epigenetic Modulator with A Unique Mechanism of Action

Target Name: EPGN

NCBI ID: G255324

EPGN

EPGN: A NAD+-Dependent Epigenetic Modulator with A Unique Mechanism of Action

Epigenetic modifiers are small molecules that have the potential to modulate the expression of genes in the body. One class of epigenetic modifiers is called NAD+-dependent modulators, which work by modulating the levels of NAD+ in cells. NAD+ is a crucial coenzyme found in all cells that plays a central role in various cellular processes, including metabolism, energy production, and signaling. Its levels are closely regulated in the body, and changes in NAD+ levels can have a significant impact on a cell's function.

One of the epigenetic modulators that has garnered a lot of interest in recent years is EPGN (100). EPGN is a NAD+-dependent modulator that has been shown to play a role in a wide range of cellular processes, including cell growth, differentiation, and survival.

EPGN is a shortened form of the enzyme NAD+-dependent dihydrolipoyl transacetylase (DHAT), which is a key enzyme in the synthesis of NAD+ from the amino acid leucine. DHAT is a key regulator of NAD+ levels in the body and is involved in the maintenance of NAD+ homeostasis in cells. EPGN is the product of a genetic mutation that has led to the substitution of a single amino acid residue from aspartic acid (D) to alanine (A) at its Asp2 position.

The substitution of Asp2 for A at EPGN's Asp2 position has resulted in a gain of function and the ability of EPGN to modulate NAD+ levels. This gain of function has made EPGN a valuable drug target and a potential biomarker for a wide range of diseases.

One of the key features of EPGN is its ability to modulate NAD+ levels in a dose-dependent manner. EPGN has been shown to increase NAD+ levels in cells under conditions of starvation or stress, while it has also been shown to decrease NAD+ levels in cells under conditions of abundance. This ability to modulate NAD+ levels makes EPGN an attractive drug target for diseases that are characterized by disruptions in NAD+ homeostasis.

EPGN has also been shown to play a role in the regulation of cellular processes that are critical for human health, such as cell growth, differentiation, and survival. For example, EPGN has been shown to be involved in the regulation of cell cycle progression, cell survival, and the response to chemotherapy. In addition, EPGN has also been shown to play a role in the regulation of inflammation and cellular signaling, which are important for the development and progression of a wide range of diseases.

EPGN has also been shown to have a unique mechanism of action that makes it different from other epigenetic modulators. Unlike other NAD+-dependent modulators, such as IDH, which has been shown to modulate NAD+ levels by converting Asp to Asn, EPGN modulates NAD+ levels by converting Asp2 to A, which is a non-catalytic substitution. This non-catalytic substitution allows EPGN to modulate NAD+ levels in a dose-dependent manner, similar to its effects on starvation or stress.

In addition to its potential therapeutic applications, EPGN also has a significant potential as a biomarker for a wide range of diseases. The ability of EPGN to modulate NAD+ levels in a dose-dependent manner makes it an attractive marker for diseases characterized by disruptions in NAD+ homeostasis. For example, EPGN has been shown to be involved in the regulation of a wide range of cellular processes, including

Protein Name: Epithelial Mitogen

Functions: Promotes the growth of epithelial cells. May stimulate the phosphorylation of EGFR and mitogen-activated protein kinases

The "EPGN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPGN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets